Drug Type Antibody fusion proteins |
Synonyms MB 4, MB4 |
Target |
Action agonists, inhibitors |
Mechanism IL-2R agonists(Interleukin-2 receptor agonists), PD-1 inhibitors(Programmed cell death protein 1 inhibitors), Tumor-associated antigen inhibitors(Tumor-associated antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Discovery | South Korea | 16 Apr 2024 |






